MedTrace Logo

Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC

NCT07603661 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2026-05-22

No results posted yet for this study

Summary

This is a prospective, single-center phase II study evaluating sintilimab plus chemotherapy as induction therapy for unresectable stage IIIC non-small cell lung cancer (NSCLC). Treatment-naive eligible patients who signed informed consent were enrolled after MDT screening. Patients received 4 cycles of sintilimab 200 mg intravenously every 3 weeks combined with chemotherapy. Post-treatment MDT evaluation was performed. Resectable patients underwent primary tumor resection and mediastinal lymph node dissection 4-6 weeks after the 4th cycle. Postoperative supraclavicular radiotherapy and guideline-recommended adjuvant therapy were determined by MDT and investigators. Unresectable patients received concurrent chemoradiotherapy.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Sintilimab plus platinum-doublet chemotherapy

Sintilimab 200 mg intravenously every 3 weeks for 4 cycles combined with platinum-doublet chemotherapy (pemetrexed/paclitaxel/nab-paclitaxel plus carboplatin/cisplatin) as induction therapy. Resectable patients undergo surgery; unresectable patients receive concurrent chemoradiotherapy.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-01
Primary Completion
2028-06-01
Completion
2029-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07603661 on ClinicalTrials.gov